Table 2.
Plasma levels of β-endorphin
| N | β-endorphin fmol/L | p | |
|---|---|---|---|
| pain patients |
80 |
26.2(3.59) |
<0.05 |
| controls |
56 |
28.2(4.63) |
|
| responder |
60 |
26.6(3.57) |
<0.01 |
| non-responder |
20 |
24.7(3.20) |
|
|
Pain patients |
|
|
|
| male OPRM1 AA |
31 |
26.8(3.25) |
<0.05 |
| male OPRM1 AG |
8 |
24.2(2.96) |
|
| female OPRM1 AA |
28 |
26.1(4.02) |
ns |
| female OPRM1 AG |
11 |
25.9(3.50) |
|
|
Controls |
|
|
|
| male OPRM1 AA |
19 |
25.8(2.17) |
ns |
| male OPRM1 AG |
6 |
31.5(9.13) |
ns |
| female OPRM1 AA |
23 |
29.3(4.60) |
ns |
| female OPRM1 AG | 8 | 28.2(1.63) | ns |
Plasma levels of the opioid peptide β-endorphin in patients with different opioid sensitivity. For further details see Methods and Results.